Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

102.400
+1.2001.19%
Volume:15.25M
Turnover:1.56B
Market Cap:178.59B
PE:186.76
High:104.000
Open:101.800
Low:100.600
Close:101.200
52wk High:109.100
52wk Low:69.550
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:1.10
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.548
ROE:5.01%
ROA:1.56%
PB:7.91
PE(LYR):186.76
PS:11.74

Loading ...

Stock Track | Innovent Biologics Plummets 5% Intraday Amid Biotech Sector Sell-off and Capital Allocation Controversy

Stock Track
·
May 28

Movement Alert|Innovent Biologics Falls 3.17% in Regular Trading, Biotech Sector Sell-off Compounded by Capital Allocation Controversy

Market Focus
·
May 28

BlackRock Boosts Stake in Innovent Bio with Additional HK$30 Million Purchase

Stock News
·
May 27

Innovent Biologics Cancer Updates Test Investor Confidence In Undervalued Shares

Simply Wall St.
·
May 24

INNOVENT BIO invests USD 690.00 million in JPMorgan and UBS structured notes, transactions classified as discloseable under HKEX rules

Bulletin Express
·
May 22

Movement Alert|Innovent Biologics Rises 3.09% in Regular Trading, Multiple New Drug Approvals Drive Consecutive Gains

Market Focus
·
May 22

Innovent reports early NSCLC data for IBI363 plus chemotherapy in Phase 1 study

Reuters
·
May 22

HUTCHMED and Innovent Jointly Announce Nmpa Approval for Elunate® (Fruquintinib) in Combination With Tyvyt® (Sintilimab Injection) for the Treatment of Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

THOMSON REUTERS
·
May 21

BRIEF-Innovent Biologics Says China's NMPA Approves Tyvyt And Elunate Combination For Advanced Renal Cell Carcinoma

Reuters
·
May 21

Innovent Bio: NMPA Greenlights TYVYT–ELUNATE Regimen for Second-Line Advanced Renal Cell Carcinoma

Bulletin Express
·
May 21

INNOVENT BIO's Combination Therapy for Advanced Kidney Cancer Receives NMPA Approval

Stock News
·
May 21

Innovent Biologics - Nmpa Approves Tyvyt and Elunate Combination for Advanced Renal Cell Carcinoma

THOMSON REUTERS
·
May 21

INNOVENT BIO (01801) Rebounds Over 4% as IBI3031 Completes Clinical Registration, Marking Major Entry into TED Precision Treatment

Stock News
·
May 21

Movement Alert|Innovent Biologics Rises 3.46% in Regular Trading, New Drug Pikanqibai Approved Amid Biotech Sector Recovery

Market Focus
·
May 21

Zieziula Gary Joseph Sells Approximately 43,431 Shares of Innovent Bio at HK$87.84 Each

Deep News
·
May 20

Innovent reports Phase Ib asthma trial data for IBI3002 IL-4Rα/TSLP antibody

Reuters
·
May 19

Hong Kong Market Closes Down 1.62%, Retreats Below 26,000 as U.S. Bond Jitters Weigh; Robotics Sector Bucks the Trend

Stock News
·
May 15

Hong Kong Stocks Midday Recap: Hang Seng Index Dips 0.87%, Robotics Sector Surges Against Market Trend

Stock News
·
May 15

Decline Persists, Innovent Bio Plunges Over 7%! Hong Kong Stock Connect Innovative Drug Sector Logs Fourth Consecutive Drop, Fund ETF 520880 Attracts Another 100 Million Yuan Inflows. Institutions Highlight Catalyst from Upcoming Industry Conference

Deep News
·
May 15

Stock Track | Innovent Biologics Plummets 8.07% in Early Trading Following Founder's Share Sale

Stock Track
·
May 15